河野太郎:日本新冠疫苗接种将於5月加快
日本行政改革大臣兼疫苗协调大臣河野太郎周一(29日)接受《路透》访问时称,当地新冠疫苗接种将於5月加快,但预定於7月展开的东京奥运会并非考虑因素。
首相菅义伟曾承诺至6月时有足够疫苗供该国1.26亿人口接种,现时由辉瑞(PFE.US)欧洲厂房缓慢供应,但料未来数月将加快。
河野表示,5月开始将不会再有供应樽颈。他补充,5月每个星期料可获得1,000万剂疫苗,至於东京奥运会应否押後或取消并非考虑因素。他续指出,阿斯利康(AZN.US)疫苗有望短期内获批,指交由厚生劳动省决定。
截至上周五(26日),有逾78万日本国民接种首剂疫苗,大多是医护人员。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.